Recombinant Mouse CD7 protein (rFc Tag)
Species
Mouse
Purity
>90 %, SDS-PAGE
Tag
rFc Tag
Activity
not tested
Cat no : Eg6283
Validation Data Gallery
Product Information
| Purity | >90 %, SDS-PAGE |
| Endotoxin | <0.1 EU/μg protein, LAL method |
| Activity |
Not tested |
| Expression | HEK293-derived Mouse CD7 protein Gln24-Pro150 (Accession# P50283) with a rabbit IgG Fc tag at the C-terminus. |
| GeneID | 12516 |
| Accession | P50283 |
| PredictedSize | 39.8 kDa |
| SDS-PAGE | 42-55 kDa, reducing (R) conditions |
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
| Reconstitution | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
| Storage Conditions |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
Background
CD7, or T-cell antigen 7 or GP40, is a transmembrane glycoprotein and a member of the immunoglobulin supergene family. CD7 is predominantly expressed on thymocytes and mature T cells, as well as natural killer (NK) cells, and it is one of the earliest antigens to appear on cells of the T-lymphocyte lineage. CD7 plays a significant role in T-cell and T-cell/B-cell interactions during early lymphoid development. It is involved in the regulation of cell signaling and biology, including T-cell activation, proliferation, and the expression of interleukin-2 receptor alpha (IL-2Rα). CD7 is not only a marker for T-cells but also has functional implications in immune cell interactions and adhesion. It can provide co-stimulatory signals and is associated with CD3 and CD45, participating in T-cell activation.
References:
1. G D Sempowski. et al. (1999). Crit Rev Immunol. 19(4):331-348. 2. StillwellR. et al.(2001). Immunol Res. 24(1): 31-52. 3. WeiSD. et al. (2005). Cell Death Dis. 9(3): 293.